Exfoliative dermatitis - Dermatitis Exfoliative
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Red (burning) Skin Syndrome ― Erythema kunye nesikali kumzimba wonke zezona mpawu ziphambili ze Dermatitis Exfoliative (Exfoliative dermatitis).
References
Erythroderma yimeko yolusu enqabileyo kodwa embi kakhulu. Nangona esona sizathu sihlala singaziwa, sinokuvuswa kukusabela kweziyobisi okanye umhlaza osisiseko. Omnye umhlaza oqhelekileyo odityaniswe ne-exfoliative dermatitis yi-T-cell lymphoma ye-cutaneous, enokuthi ingabonisi zimpawu kwiinyanga okanye iminyaka emva kokuba imeko yolusu iqalile. Ngokuqhelekileyo, ukulaliswa esibhedlele kuyafuneka kuvavanyo lokuqala kunye nonyango. Izigulana ezinesifo esibangelwa ngamachiza ngokubanzi zinembono entle yexesha elide, nangona iimeko ezingenasizathu esicacileyo zikholisa ukuba nekhosi ephindaphindayo neyiyekisayo. I-prognosis yamatyala anxulunyaniswa nomhlaza ngokuqhelekileyo ixhomekeke kwindlela umhlaza oqhubeka ngayo.
Erythroderma is a rare but serious skin condition. While the exact cause is often unknown, it can be triggered by a drug reaction or an underlying cancer. One common cancer linked to exfoliative dermatitis is cutaneous T-cell lymphoma, which might not show symptoms for months or even years after the skin condition starts. Usually, hospitalization is needed for initial assessment and treatment. Patients with drug-induced disease generally have a good long-term outlook, though cases without a clear cause tend to have a recurring and remitting course. The prognosis for cases linked to cancer typically depends on how the cancer progresses.
Erythroderma is a rare but serious skin condition. While the exact cause is often unknown, it can be triggered by a drug reaction or an underlying cancer. One common cancer linked to exfoliative dermatitis is cutaneous T-cell lymphoma, which might not show symptoms for months or even years after the skin condition starts. Usually, hospitalization is needed for initial assessment and treatment. Patients with drug-induced disease generally have a good long-term outlook, though cases without a clear cause tend to have a recurring and remitting course. The prognosis for cases linked to cancer typically depends on how the cancer progresses.
Ibonisa ubukhulu becala ububomvu kunye nokugquma okugquma ngaphezulu kwe-90% yomzimba. Le meko luphawu olubonakalayo lwemiba eyahlukeneyo yezempilo efana ne-psoriasis, i-eczema, okanye impendulo kumayeza athile.
It characteristically demonstrates diffuse erythema and scaling of greater than 90% of the body surface area. It is a reaction pattern and cutaneous manifestation of a myriad of underlying ailments, including psoriasis and eczema, or a reaction to the consumption of certain drugs.
It characteristically demonstrates diffuse erythema and scaling of greater than 90% of the body surface area. It is a reaction pattern and cutaneous manifestation of a myriad of underlying ailments, including psoriasis and eczema, or a reaction to the consumption of certain drugs.
Isizathu esiqhelekileyo se-erythroderma kukugqithiswa kwesifo sesikhumba esingaphantsi, njenge-psoriasis, i-contact dermatitis, i-seborrheic dermatitis, i-lichen planus, i-pityriasis rubra pilaris okanye ukuphendulwa kweziyobisi, ezifana nokusetyenziswa kwe-topical steroids. I-manefestation yokuqala ayixhaphaki kwaye idla ngokubonwa kwiimeko ze-T-cell lymphoma ye-cutaneous. Kuba kubalulekile ukuyohlula kwi-cutaneous T cell lymphoma, i-biopsy iyenziwa.